scholarly journals Therapeutic Role of Dilatation And Curettage, Oral Contraceptive Pills and Ormeloxifene (Sevista) in Abnormal Uterine Bleeding

2015 ◽  
Vol 2 (1) ◽  
Keyword(s):  
Oral Contraceptive ◽  
Abnormal Uterine Bleeding ◽  
Uterine Bleeding ◽  
Therapeutic Role ◽  
Oral Contraceptive Pills ◽  
Dilatation And Curettage ◽  
Contraceptive Pills

scholarly journals Extreme Anemia (Hemoglobin 1.8 g/dL) Secondary to Abnormal Uterine Bleeding

2017 ◽  
Vol 2017 ◽  
pp. 1-3 ◽  
Author(s):  
Ketaki Panse ◽  
Rachel Regn ◽  
Jonathan May
Keyword(s):  
Blood Pressure ◽  
Emergency Department ◽  
Heart Rate ◽  
Oral Contraceptive ◽  
Abnormal Uterine Bleeding ◽  
Uterine Bleeding ◽  
Shortness Of Breath ◽  
Oral Contraceptive Pills ◽  
Fibroid Uterus ◽  
Contraceptive Pills

We present the case of a 39-year-old G5P5 woman who presented to the emergency department with complaints of shortness of breath, lightheadedness, and excessive uterine bleeding for 14 days, with a heart rate of 123 and a blood pressure of 137/65. Menses had been heavy for several months. A hemoglobin of 1.8 g/dL was discovered. An ultrasound revealed an 11.8 cm fibroid uterus, and the patient was transfused with 6 units of blood and placed on oral contraceptive pills.

scholarly journals Comparative study of ormeloxifene and low dose oral contraceptive pill for the treatment of dysfunctional uterine bleeding in peri-menopausal age group

2021 ◽  
Vol 10 (8) ◽  
pp. 3112
Author(s):  
Maitri Shah ◽  
Chirayu Parmar ◽  
Riddhi Gor
Keyword(s):  
Oral Contraceptive ◽  
Blood Loss ◽  
Uterine Bleeding ◽  
T Test ◽  
Wilcoxon Test ◽  
Age Group ◽  
Dysfunctional Uterine Bleeding ◽  
Oral Contraceptive Pills ◽  
Combined Oral Contraceptive ◽  
Contraceptive Pills

Background: Dysfunctional uterine bleeding (DUB) is the most common menstrual disorder of women in any age group and is a diagnosis of exclusion. Medical management of menorrhagia is a difficult task as there are wide variations in the available drugs and a lot of different regimes are available. Present study evaluates efficacy and safety of ormeloxifene a selective estrogen receptor modulator (SERMs) as compared to combined oral contraceptive pills in treatment of dysfunctional uterine bleeding in perimenopausal women.Methods: Total 60 patients meeting with our inclusion and exclusion criteria were enrolled in the study over a time period of 6 months and were further divided randomly into two groups. One group was given Ormeloxifene and the other group was treated with combined oral contraceptive pills (COCP) over a period of six months. The outcome variables noted were pictorial blood loss assessment chart (PBAC) score, Hb level and combined endometrial thickness (CET). Quantitative variables were compared using independent t test/Mann-Whitney test between the two groups and paired t Test/Wilcoxon test was used for comparison between pre and post within the group.Results: Both ormeloxifene and COCP significantly reduce blood loss in these patients evidenced by decrease of PBAC score, rise in hemoglobin levels and decrease in CET levels. However, ormeloxifene was found to be superior to COCP in reducing the menstrual blood loss. Ormeloxifene was also tolerated better compared to COCP with fewer side effects experienced by patients.

scholarly journals Diagnostic role of hysteroscopy in abnormal uterine bleeding: a comparative study of hysteroscopy findings with histopathology from Mysore, South India

2019 ◽  
Vol 8 (2) ◽  
pp. 398
Author(s):  
Mamatha Shivanagappa ◽  
Vinutha K. Veerabhadrappa ◽  
Madhumitha Mahesh
Keyword(s):  
Diagnostic Technique ◽  
Abnormal Uterine Bleeding ◽  
Uterine Bleeding ◽  
Normal Endometrium ◽  
Medical College ◽  
Dilatation And Curettage ◽  
Diagnostic Role ◽  
Diagnostic Hysteroscopy ◽  
Diagnostic Work

Background: Dilatation and curettage has long been the diagnostic gold standard for abnormal uterine bleeding. However, even a trained gynecological curettes at best 70-80% of the endometrium. Hysteroscopy is gaining acceptability over other diagnostic technique like dilatation and curettage, hysterosalpingogram and ultrasound. The objective of this study is to find out the role of hysteroscopy in abnormal uterine bleeding and to compare hysteroscopy findings with histopathology.Methods: Fifty patients in perimenopausal age group with abnormal uterine bleeding attending JSS Medical College and Hospital Mysore, during the period 1999-2001 were studied by diagnostic hysteroscopy followed by dilatation and curettage.Results: Mean age of the study group was 44.3% years (±2.5 SD). Menorrhagia was the commonest symptom and was found in 68% of the patients. Diagnostic hysteroscopy identified 23 cases as Normal endometrium, 16 cases as endometrial hyperplasia, 3 cases as atrophic endometrium, 4 cases as endometrial polyp, 4 cases as fibroids. Compared with histopathological findings as definitive diagnosis, hysteroscopy correctly picked up 19 cases of (86.9%), normal endometrium, 12 cases of hyperplasia (75%), 3 cases of atrophic endometrium (100%), 4 cases of polyps (100%), and 4 cases of fibroid (100%).Conclusions: Hysteroscopy should be considered as a basic and essential diagnostic procedure in the diagnostic work up of abnormal uterine bleeding. 

scholarly journals Ormeloxifene versus combined oral contraceptive pills to control blood loss in cases of dysfunctional uterine bleeding

2019 ◽  
Vol 8 (12) ◽  
pp. 4909
Author(s):  
Ankita Gupta ◽  
Rishika Raj
Keyword(s):  
Oral Contraceptive ◽  
Blood Loss ◽  
Endometrial Thickness ◽  
Uterine Bleeding ◽  
Menstrual Blood ◽  
Control Group ◽  
Dysfunctional Uterine Bleeding ◽  
Oral Contraceptive Pills ◽  
Combined Oral Contraceptive ◽  
Contraceptive Pills

Background: Dysfunctional uterine bleeding is one of the most often encountered gynecologic problems causing anemia, reduced quality of life and unnecessary hysterectomies. A prospective study was conducted on women with DUB to study the effect of ormeloxifene versus combined oral contraceptive pills in controlling blood loss in them.Methods: 100 Women with DUB were enrolled randomly in three groups. After baseline assessment each patient in group A was treated with iron tablets, containing 100 mg elemental iron and folic acid 1.5 mg, for three months and were termed as control group. Group B patients were treated with ormeloxifene in dose of 60 mg twice a week for twelve weeks. Group C patients were treated with combined oral contraceptive pills for twenty- one days starting from third day of their LMP. The treatment was continued for three consecutive cycles. The efficacy of the studied drugs was analyzed by comparing the baseline and post treatment PBAC score, haemoglobin level and endometrial thickness, using appropriate statistical tests.Results: Ormeloxifene was more effective than only iron or combined oral contraceptive therapy in controlling menstrual blood loss (79.11% versus 58.57%). There was a reduction in endometrial thickness in group receiving ormeloxifene as well as in the group receiving combined oral contraceptive pills (p=0.486), however this was statistically not significant.Conclusions: Ormeloxifene was significantly better than combined OCP in reduction of menstrual blood flow in cases of DUB. It has better compliance and marked improvement in subjective symptoms as compared to OCP.

scholarly journals Tamoxifen for treatment of abnormal uterine bleeding in etonorgstrel implant users: a randomized clinical trial

2019 ◽  
Vol 8 (11) ◽  
pp. 4462
Author(s):  
Ahmed N. Fetih ◽  
Ahmed M. Abbas ◽  
Fatma A. Kamel ◽  
Ihab H. El Nashar
Keyword(s):  
Oral Contraceptive ◽  
Treatment Time ◽  
Abnormal Uterine Bleeding ◽  
Once Daily ◽  
Oral Contraceptive Pills ◽  
Contraceptive Pills ◽  
Tamoxifen Group ◽  
Group A ◽  
The Mean ◽  
Group B

Background: The current study aims to compare the use of tamoxifen and oral contraceptive pills in women using implanon and complain with irregular uterine bleeding.Methods: Women attended family planning clinic using implanon presented by bleeding were invited to participate in the study. They were randomized into two groups: Group A: 100 women received Tamoxifen 10 mg twice daily for 10 days taken at the onset of an episode of bleeding or spotting episode. Group B: 100 women received Combined oral contraceptive pills (microcept) once daily for 21 days take at the onset of an episode of bleeding or spotting episode.Results: No difference regarding the baseline criteria of both groups. No difference between both groups regarding the duration of irregular bleeding in the implanon users (p=0.090). Additionally, the number of bleeding days and spotting in the last month was similar in both groups (p=0.554). The percentage of women who stopped bleeding during the period of treatment is 84% in the tamoxifen group and 92% in the COCs group, but the COCs needs longer treatment time, where the mean of days required to stop bleeding is 5.03±1.8 days in the tamoxifen group and 6.5±2.5 in the COCs group. Headache and nausea were the most prominent adverse effects found in the COCs group (p=0.000).Conclusions: Oral administration of tamoxifen 10 mg twice daily for 10 days is effective on stopping bleeding attacks in implanon users.

scholarly journals A study to compare the efficacy of ormeloxifene with norethisterone and conventional oral contraceptive pills

2017 ◽  
Vol 6 (10) ◽  
pp. 4469
Author(s):  
Monica Chauhan ◽  
Neena Gupta ◽  
Seema Dwivedi ◽  
Shaily Agarwal
Keyword(s):  
Oral Contraceptive ◽  
Comparative Evaluation ◽  
Randomized Study ◽  
Uterine Bleeding ◽  
Subjective Improvement ◽  
Dysfunctional Uterine Bleeding ◽  
Oral Contraceptive Pills ◽  
Group Iii ◽  
Contraceptive Pills ◽  
Group I

Background: Dysfunctional uterine bleeding is one of the commonest conditions for which patients seek advice in gynaecological outpatient department. Objective of present study was comparative evaluation of ormeloxifene with norethisterone and conventional oral contraceptive pills in dysfunctional uterine bleeding.Methods: This randomized study was conducted on 300 cases of dysfunctional uterine bleeding and they were distributed into three groups. group I were given ormeloxifene 60 mg biweekly for first 12 weeks followed by 60 mg weekly for next 12 weeks. Group II were given norethisterone 5 mg BD from 5th to 25th day of cycle and group III were given oral contraceptive pills from 5th to 25th day of cycle.Results: Subjective improvement was outstanding in group I in comparison to other two groups. There was also statistically significant increase in Hb g/dl and statistically significant decrease in endometrial thickness.Conclusions: Ormeloxifene was found to be superior to both norethisterone and conventional OCPs.

scholarly journals The Role of Oral Contraceptive Pills in Hidradenitis Suppurativa: A Cohort Study

Life ◽  
2021 ◽  
Vol 11 (7) ◽  
pp. 697
Author(s):  
Trinidad Montero-Vilchez ◽  
Andrea Valenzuela-Amigo ◽  
Carlos Cuenca-Barrales ◽  
Salvador Arias-Santiago ◽  
Ana Leyva-García ◽  
...  
Keyword(s):  
Oral Contraceptive ◽  
Menstrual Cycle ◽  
Hidradenitis Suppurativa ◽  
Prospective Observational Study ◽  
Disease Duration ◽  
Concomitant Therapy ◽  
Oral Contraceptive Pills ◽  
Contraceptive Pills ◽  
First Time

There is a need to establish the role of antiandrogens as an alternative or concomitant therapy for hidradenitis suppurativa (HS). Thus, the objectives of this study are (1) to assess the effectiveness of oral contraceptive pills (OCPs) at week 12 in HS women, and (2) to describe the clinical profile of patients receiving oral contraceptive pills (OCPs). A prospective observational study was designed. This study included 100 participants, 50 women with HS who started OCPs for the first time at our HS Clinic and 50 participants without OCP treatment. The main outcome of interest was the percentage of reduction in total abscess and inflammatory nodule (AN) count at week 12. Thirty-three women received combined OCPs and 17 non-combined OCP. HS patients with OCPs treatment were younger (31.7 vs. 40.9 years, p < 0.001), thinner (28.62 vs. 33.35 kg/m2), and have a higher number of areas affected (2.32 vs. 1.38, p = 0.02) than those without OCPs. After 12-weeks of treatment, it was observed that the percentage of AN reduction was higher in HS women receiving OCP than in patients without OCP (53.9% vs. 38.42%, p = 0.049). It was observed that OCP prescription (β = 3.79, p = 0.034) and concomitant therapy (β = 3.91, p = 0.037) were independently associated with a higher % AN when controlling for disease duration, concomitant therapy, and treatment with/without OCP (R^2 = 0.67). The factors potentially associated with the percentage AN reduction at week 12 in HS women treated with OCPs were disease duration (β = −1.327, p = 0.052), concomitant therapy (β = 11.04, p = 0.079), and HS worsening with the menstrual cycle (β = 10.55, p = 0.087). In conclusion, OCPs might be effective for improving AN count in women with HS. Women whose HS worsens in relation to the menstrual cycle and have a shorter disease may benefit more from the therapeutic effect of OCPs.

Sign in / Sign up

Export Citation Format

Share Document